APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke
NCT ID: NCT04457479
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
190 participants
OBSERVATIONAL
2020-11-02
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
REcanalization of Distal Cerebral Vessels in Acute Stroke Using ApeRio®
NCT04479020
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
NCT05983757
Biomarkers algOrithm for strOke diagnoSis and Treatment Resistance Prediction
NCT04726839
Mechanical Thrombectomy in Acute Ischemic Stroke Beyond the Time of Window
NCT04087382
Mechanical Thrombectomy of Acute Ischemic Stroke Anterior Circulation Distal Vessel Occlusion
NCT06427187
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke
Study Type: prospective, multicenter, single-armed, open-label
Participants: 8 participating centers in Germany
PI: Dr. Christian Mathys, Evangelisches Krankenhaus Oldenburg, Germany
Estimated Enrolment: 190 patients treated with APERIO® HYBRID(17/21) Thrombectomy Device as a result of an acute stroke
Follow up: 3 months
Estimated Final Assessment: Mid to End of 2023
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pre stroke mRS ≥ 3
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acandis GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Evangelisches Krankenhaus Oldenburg
Oldenburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HYBRID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.